Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors
暂无分享,去创建一个
K. Morrissey | F. Cattaruzza | Milton To | V. Schellenberger | M. Derynck | C. Koski | B. Irving | V. Podust | M. Hammond | A. Nazeer | Michael Fox | Deena A Rennerfeldt | Z. Lange | A. Henkensiefken | Lucas Y Liu | V. Pete Yeung | Sharon Lam